RU2265659C2 - Штамм птичьего реовируса, вакцина, содержащая указанный реовирус, способ получения птичьих реовирусов, способ изготовления вакцины и способ борьбы с патологиями птицы, вызываемыми птичьими реовирусами - Google Patents
Штамм птичьего реовируса, вакцина, содержащая указанный реовирус, способ получения птичьих реовирусов, способ изготовления вакцины и способ борьбы с патологиями птицы, вызываемыми птичьими реовирусами Download PDFInfo
- Publication number
- RU2265659C2 RU2265659C2 RU2000102307/13A RU2000102307A RU2265659C2 RU 2265659 C2 RU2265659 C2 RU 2265659C2 RU 2000102307/13 A RU2000102307/13 A RU 2000102307/13A RU 2000102307 A RU2000102307 A RU 2000102307A RU 2265659 C2 RU2265659 C2 RU 2265659C2
- Authority
- RU
- Russia
- Prior art keywords
- avian
- reovirus
- vaccine
- reoviruses
- avian reovirus
- Prior art date
Links
- 241001516406 Avian orthoreovirus Species 0.000 title claims abstract description 105
- 229960005486 vaccine Drugs 0.000 title claims abstract description 63
- 238000000034 method Methods 0.000 title claims abstract description 24
- 241000271566 Aves Species 0.000 title claims description 27
- 241000702263 Reovirus sp. Species 0.000 title abstract description 37
- 230000007170 pathology Effects 0.000 title description 9
- 244000144977 poultry Species 0.000 claims abstract description 28
- 241000702244 Orthoreovirus Species 0.000 claims abstract description 23
- 230000001575 pathological effect Effects 0.000 claims abstract description 21
- 208000015181 infectious disease Diseases 0.000 claims description 42
- 238000011081 inoculation Methods 0.000 claims description 9
- 230000002238 attenuated effect Effects 0.000 claims description 8
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 239000000758 substrate Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 244000052769 pathogen Species 0.000 claims description 4
- 238000009395 breeding Methods 0.000 claims description 2
- 230000001488 breeding effect Effects 0.000 claims description 2
- 230000000415 inactivating effect Effects 0.000 claims description 2
- 241000702247 Reoviridae Species 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
- 238000002255 vaccination Methods 0.000 abstract description 27
- 235000013594 poultry meat Nutrition 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 8
- 239000000126 substance Substances 0.000 abstract description 3
- 239000000427 antigen Substances 0.000 abstract description 2
- 108091007433 antigens Proteins 0.000 abstract description 2
- 102000036639 antigens Human genes 0.000 abstract description 2
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 241000287828 Gallus gallus Species 0.000 description 77
- 235000013330 chicken meat Nutrition 0.000 description 46
- 241000700605 Viruses Species 0.000 description 44
- 241001465754 Metazoa Species 0.000 description 37
- 210000002966 serum Anatomy 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 21
- 230000000890 antigenic effect Effects 0.000 description 18
- 230000000120 cytopathologic effect Effects 0.000 description 13
- 210000002683 foot Anatomy 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 12
- 239000008280 blood Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 11
- 201000010099 disease Diseases 0.000 description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- 235000013305 food Nutrition 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 238000002965 ELISA Methods 0.000 description 10
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 9
- 206010053759 Growth retardation Diseases 0.000 description 9
- 238000010790 dilution Methods 0.000 description 9
- 239000012895 dilution Substances 0.000 description 9
- 210000003608 fece Anatomy 0.000 description 9
- 231100000001 growth retardation Toxicity 0.000 description 9
- 229940031551 inactivated vaccine Drugs 0.000 description 9
- 230000000968 intestinal effect Effects 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 8
- 230000002458 infectious effect Effects 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 230000003902 lesion Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 206010061218 Inflammation Diseases 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 208000004760 Tenosynovitis Diseases 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 230000002779 inactivation Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002962 plaque-reduction assay Methods 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 230000003612 virological effect Effects 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 101100423891 Caenorhabditis elegans qars-1 gene Proteins 0.000 description 4
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 206010025476 Malabsorption Diseases 0.000 description 4
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000008774 maternal effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000009257 reactivity Effects 0.000 description 4
- 238000010254 subcutaneous injection Methods 0.000 description 4
- 239000007929 subcutaneous injection Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- 208000004232 Enteritis Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229940001442 combination vaccine Drugs 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 231100000676 disease causative agent Toxicity 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 238000010185 immunofluorescence analysis Methods 0.000 description 3
- 239000012678 infectious agent Substances 0.000 description 3
- 208000028774 intestinal disease Diseases 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 229940124590 live attenuated vaccine Drugs 0.000 description 3
- 229940023012 live-attenuated vaccine Drugs 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000000644 propagated effect Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 239000002356 single layer Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000711404 Avian avulavirus 1 Species 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000711450 Infectious bronchitis virus Species 0.000 description 2
- 231100000678 Mycotoxin Toxicity 0.000 description 2
- 206010048685 Oral infection Diseases 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 208000008104 Reoviridae Infections Diseases 0.000 description 2
- 241000711955 Turkey rhinotracheitis virus Species 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 210000003555 cloaca Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002845 discoloration Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013601 eggs Nutrition 0.000 description 2
- 210000002257 embryonic structure Anatomy 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 208000037824 growth disorder Diseases 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000001872 metatarsal bone Anatomy 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 239000002636 mycotoxin Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 230000036435 stunted growth Effects 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 2
- 210000003501 vero cell Anatomy 0.000 description 2
- 239000011534 wash buffer Substances 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 208000010370 Adenoviridae Infections Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 206010003274 Arthritis viral Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 206010006811 Bursitis Diseases 0.000 description 1
- 206010009719 CNS ventriculitis Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 241000702626 Infectious bursal disease virus Species 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000272458 Numididae Species 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033603 Pancreatic atrophy Diseases 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 208000027954 Poultry disease Diseases 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 239000005862 Whey Substances 0.000 description 1
- 102000007544 Whey Proteins Human genes 0.000 description 1
- 108010046377 Whey Proteins Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 229910000318 alkali metal phosphate Inorganic materials 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000003323 beak Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- -1 for example Substances 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 150000002540 isothiocyanates Chemical class 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000001865 kupffer cell Anatomy 0.000 description 1
- 208000030175 lameness Diseases 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 210000003789 metatarsus Anatomy 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000009374 poultry farming Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-N sulfurothioic S-acid Chemical compound OS(O)(=O)=S DHCDFWKWKRSZHF-UHFFFAOYSA-N 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/15—Reoviridae, e.g. calf diarrhea virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12211—Orthoreovirus, e.g. mammalian orthoreovirus
- C12N2720/12234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99200259 | 1999-01-29 | ||
| EP99200259.2 | 1999-01-29 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2000102307A RU2000102307A (ru) | 2003-07-10 |
| RU2265659C2 true RU2265659C2 (ru) | 2005-12-10 |
Family
ID=8239847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2000102307/13A RU2265659C2 (ru) | 1999-01-29 | 2000-01-28 | Штамм птичьего реовируса, вакцина, содержащая указанный реовирус, способ получения птичьих реовирусов, способ изготовления вакцины и способ борьбы с патологиями птицы, вызываемыми птичьими реовирусами |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6951650B1 (enExample) |
| EP (1) | EP1024189B1 (enExample) |
| JP (2) | JP4659942B2 (enExample) |
| KR (1) | KR100583259B1 (enExample) |
| AT (1) | ATE292674T1 (enExample) |
| AU (1) | AU759179B2 (enExample) |
| BR (1) | BR0000190A (enExample) |
| CA (1) | CA2297345C (enExample) |
| DE (1) | DE60019178T2 (enExample) |
| ES (1) | ES2240005T3 (enExample) |
| HU (1) | HU225434B1 (enExample) |
| MX (1) | MXPA00001001A (enExample) |
| PL (1) | PL192277B1 (enExample) |
| PT (1) | PT1024189E (enExample) |
| RU (1) | RU2265659C2 (enExample) |
| ZA (1) | ZA200000370B (enExample) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2701808C2 (ru) * | 2014-10-03 | 2019-10-01 | Интервет Интернэшнл Б.В. | Вакцина широкого спектра действия против реовируса птиц |
| RU2708316C2 (ru) * | 2014-01-29 | 2019-12-05 | Дзе Юниверсити Оф Джорджиа Рисерч Фаундейшн, Инк. | Вакцины на основе реовирусов птиц |
| RU2742250C2 (ru) * | 2016-01-07 | 2021-02-04 | Гавиш-Галили Био Эпликейшнз, Лтд | Оптимизированный полипептид для субъединичной вакцины против реовируса птиц |
| RU2830499C1 (ru) * | 2019-12-02 | 2024-11-20 | Юниерсити Оф Джорджия Рисёрч Фаундейшн, Инк. | Аттенуированные штаммы реовируса птиц 94826 c140 и 96139 c140 |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006503863A (ja) * | 2002-09-16 | 2006-02-02 | ワイス | トリ吸収不良症候群に関与するウイルスを含有するワクチンおよびその投与法 |
| JP2006516146A (ja) * | 2002-10-09 | 2006-06-22 | アクゾ・ノベル・エヌ・ベー | トリレオウイルスにより引き起こされる神経学的症状の治療および予防方法ならびに新規付随的特徴 |
| WO2008076518A2 (en) * | 2006-10-25 | 2008-06-26 | University Of Georgia Research Foundation, Inc. | Reovirus compositions and methods of use |
| BRPI0910185A2 (pt) * | 2008-06-26 | 2015-12-01 | Ceva Sante Animale S A | sorotipo de reovírus aviário isolado, reovírus aviário isolado, peptídeos, vacina, antisoro isolado, anticorpo isolado, método para proteção de aves, método para detecção ou quantificação de reovírus em aves, recipiente para vacinação de aves, kit para vacinação de aves, kit de diagnóstico, linhagem celular derivada da lmh |
| WO2010059899A2 (en) * | 2008-11-20 | 2010-05-27 | University Of Georgia Research Foundation, Inc. | Vaccine for runting-stunting syndrome |
| CA2725435C (en) | 2009-12-15 | 2023-01-03 | University Of Saskatchewan | Vaccines for inclusion body hepatitis |
| KR101600959B1 (ko) | 2013-06-18 | 2016-03-08 | 단국대학교 산학협력단 | 가금 레오바이러스 시그마 c 단백질의 항원 결정기를 포함하는 재조합 단백질 및 이에 대한 항체 |
| CN104711240B (zh) * | 2015-03-18 | 2017-10-10 | 广西壮族自治区兽医研究所 | 禽呼肠孤病毒σA蛋白及其相关生物材料的应用 |
| CN108794627A (zh) * | 2018-07-03 | 2018-11-13 | 重庆永健生物技术有限责任公司 | 一种鸭呼肠孤病毒精制卵黄抗体的制备方法 |
| CN111000992A (zh) * | 2019-12-19 | 2020-04-14 | 广州渔跃生物技术有限公司 | 一种鸭呼肠孤病毒、鸭坦布苏病毒和鸭腺病毒三联灭活疫苗及其制备方法 |
| CN116478937B (zh) * | 2023-06-12 | 2023-08-18 | 中国农业科学院哈尔滨兽医研究所（中国动物卫生与流行病学中心哈尔滨分中心） | 基因iii型禽呼肠孤病毒变异株及其在制备疫苗中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525342A (en) * | 1994-05-20 | 1996-06-11 | Akzo Nobel, N.V. | Reovirus strain 2177 and vaccine containing same |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4559229A (en) * | 1982-07-20 | 1985-12-17 | Research Foundation | Avian proventriculitis vaccine |
-
2000
- 2000-01-25 ES ES00200256T patent/ES2240005T3/es not_active Expired - Lifetime
- 2000-01-25 EP EP00200256A patent/EP1024189B1/en not_active Expired - Lifetime
- 2000-01-25 DE DE60019178T patent/DE60019178T2/de not_active Expired - Lifetime
- 2000-01-25 AT AT00200256T patent/ATE292674T1/de not_active IP Right Cessation
- 2000-01-25 PT PT00200256T patent/PT1024189E/pt unknown
- 2000-01-25 JP JP2000015930A patent/JP4659942B2/ja not_active Expired - Fee Related
- 2000-01-27 BR BR0000190-2A patent/BR0000190A/pt not_active Application Discontinuation
- 2000-01-27 ZA ZA200000370A patent/ZA200000370B/xx unknown
- 2000-01-27 CA CA2297345A patent/CA2297345C/en not_active Expired - Fee Related
- 2000-01-28 US US09/493,484 patent/US6951650B1/en not_active Expired - Lifetime
- 2000-01-28 MX MXPA00001001A patent/MXPA00001001A/es active IP Right Grant
- 2000-01-28 PL PL338118A patent/PL192277B1/pl unknown
- 2000-01-28 RU RU2000102307/13A patent/RU2265659C2/ru not_active IP Right Cessation
- 2000-01-28 HU HU0000362A patent/HU225434B1/hu not_active IP Right Cessation
- 2000-01-28 AU AU13629/00A patent/AU759179B2/en not_active Ceased
- 2000-01-28 KR KR1020000004329A patent/KR100583259B1/ko not_active Expired - Fee Related
-
2010
- 2010-11-17 JP JP2010256592A patent/JP2011092190A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5525342A (en) * | 1994-05-20 | 1996-06-11 | Akzo Nobel, N.V. | Reovirus strain 2177 and vaccine containing same |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2708316C2 (ru) * | 2014-01-29 | 2019-12-05 | Дзе Юниверсити Оф Джорджиа Рисерч Фаундейшн, Инк. | Вакцины на основе реовирусов птиц |
| RU2724497C2 (ru) * | 2014-01-29 | 2020-06-23 | Дзе Юниверсити Оф Джорджиа Рисерч Фаундейшн, Инк. | Вакцины на основе реовирусов птиц |
| RU2701808C2 (ru) * | 2014-10-03 | 2019-10-01 | Интервет Интернэшнл Б.В. | Вакцина широкого спектра действия против реовируса птиц |
| RU2742250C2 (ru) * | 2016-01-07 | 2021-02-04 | Гавиш-Галили Био Эпликейшнз, Лтд | Оптимизированный полипептид для субъединичной вакцины против реовируса птиц |
| US11541111B2 (en) | 2016-01-07 | 2023-01-03 | Gavish-Galilee Bio Applications, Ltd. | Optimized polypeptide for a subunit vaccine against avian reovirus |
| RU2830499C1 (ru) * | 2019-12-02 | 2024-11-20 | Юниерсити Оф Джорджия Рисёрч Фаундейшн, Инк. | Аттенуированные штаммы реовируса птиц 94826 c140 и 96139 c140 |
Also Published As
| Publication number | Publication date |
|---|---|
| AU1362900A (en) | 2000-08-03 |
| US6951650B1 (en) | 2005-10-04 |
| EP1024189A1 (en) | 2000-08-02 |
| CA2297345C (en) | 2010-07-13 |
| PL192277B1 (pl) | 2006-09-29 |
| MXPA00001001A (es) | 2002-03-08 |
| PT1024189E (pt) | 2005-08-31 |
| HU225434B1 (en) | 2006-11-28 |
| AU759179B2 (en) | 2003-04-10 |
| EP1024189B1 (en) | 2005-04-06 |
| HUP0000362A3 (en) | 2005-04-28 |
| KR20010069166A (ko) | 2001-07-23 |
| BR0000190A (pt) | 2001-08-21 |
| ATE292674T1 (de) | 2005-04-15 |
| JP4659942B2 (ja) | 2011-03-30 |
| HU0000362D0 (en) | 2000-04-28 |
| DE60019178T2 (de) | 2005-09-08 |
| CA2297345A1 (en) | 2000-07-29 |
| ZA200000370B (en) | 2000-08-07 |
| JP2011092190A (ja) | 2011-05-12 |
| JP2000295986A (ja) | 2000-10-24 |
| KR100583259B1 (ko) | 2006-05-25 |
| ES2240005T3 (es) | 2005-10-16 |
| PL338118A1 (en) | 2000-07-31 |
| HUP0000362A2 (hu) | 2000-11-28 |
| DE60019178D1 (de) | 2005-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011092190A (ja) | トリレオウイルスの新規抗原クラス | |
| DK163133B (da) | Biologisk ren praeparation af en smitsom bronchitis-virusstamme | |
| US8178110B2 (en) | Reovirus compositions and methods of use | |
| US4559229A (en) | Avian proventriculitis vaccine | |
| US20020048806A1 (en) | Poultry virus isolates and method | |
| JP2002045175A (ja) | 卵内投与用のｉｂｄｖ株 | |
| US20080317776A1 (en) | Vaccines Containing Viruses Involved in Avian Malabsorption Syndrome and Methods of Administration Therefor | |
| CN100384988C (zh) | 2型鸡星状病毒 | |
| CA2337618C (en) | Chicken anaemia viruses of low pathogenicity | |
| Khodashenas et al. | Isolation and characterization of avian Reoviruses from the cases of malabsorption syndrome and arthritis/tenosynovitis in chickens | |
| Abd El-Ghany | Forms of avian reovirus in poultry production: An overview | |
| RU2264458C1 (ru) | Штамм n101 вниизж rotavirus крупного рогатого скота для изготовления диагностических, вакцинных и лечебных препаратов | |
| US20040157212A1 (en) | Novel Avian reoviruses capable of immediate growth on mammalian cells | |
| Aghakhan | Studies on selected avian adenoviruses | |
| Srivastavaa | Studies on cytopathogenicity of egg drop syndrome-76 virus | |
| Elneel | A STUDY ON EGG DROP SYNDROME 76 (EDS76) IN KHARTOUM STATE | |
| HUP0002033A2 (hu) | A csirke parvovírus által okozott betegségek elleni oltóanyag |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PC4A | Invention patent assignment |
Effective date: 20070119 |
|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20170129 |